Sorrento Therapeutics (SRNEQ) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free SRNEQ Stock Alerts $0.02 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSorrento wins DoJ’s venue-based challenge to bankruptcy filingmsn.com - March 12 at 1:55 PMLatham, Jackson Walker avoid sanctions over bankruptcy forum shopping disputereuters.com - February 29 at 9:37 PMVirpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex Pharmaceuticalsbizjournals.com - February 27 at 12:46 PMSorrento Therapeutics Stock (OTC:SRNEQ) Dividends: History, Yield and Datesbenzinga.com - February 22 at 1:47 PMSorrento faked venue in bankruptcy filing, Justice Department saysmsn.com - February 21 at 3:10 PMSorrento Therapeutics Inc (SRNEQ) Earnings Dates & Reportsinvesting.com - November 18 at 8:12 AMScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Pricefinance.yahoo.com - October 7 at 11:28 PMScilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Companyfinance.yahoo.com - October 3 at 1:42 PMScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.finance.yahoo.com - September 21 at 6:45 PMScilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)finance.yahoo.com - September 14 at 10:03 AMScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidderfinance.yahoo.com - September 13 at 9:14 AMSorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19finance.yahoo.com - September 12 at 1:12 PMScilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Informationfinance.yahoo.com - September 11 at 9:57 AMSorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patientsfinance.yahoo.com - September 7 at 11:13 AMSorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holdersfinance.yahoo.com - July 27 at 9:32 AMSorrento Announces Launch of Voluntary Offering to Dividend Short Holders with Deadline to Participate by July 27, 2023finance.yahoo.com - July 21 at 10:10 AMSorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holdersfinance.yahoo.com - July 20 at 1:10 PMSorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Studyfinance.yahoo.com - July 5 at 9:32 AMSorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19finance.yahoo.com - June 26 at 11:45 AMSorrento Therapeutics, Inc.'s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stockfinance.yahoo.com - June 15 at 9:58 AMScilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stockfinance.yahoo.com - June 15 at 9:58 AMSorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparednessfinance.yahoo.com - June 13 at 5:05 PMSorrento Therapeutics Inc. (SRNEQ)nasdaq.com - May 27 at 3:16 PMScilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividendfinance.yahoo.com - April 26 at 12:06 AMSorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividendfinance.yahoo.com - April 25 at 7:06 PMBankrupt Drugmaker Sorrento’s Scilex Unit Explores Stock Salefinance.yahoo.com - April 13 at 11:08 PMScilex Holding Company Announces Postponement of Annual Meeting of Stockholdersfinance.yahoo.com - April 5 at 6:03 PMSorrento Therapeutics Inc (SRNEQ)investing.com - March 18 at 1:31 PMCourt Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against NantPharma, LLCfinance.yahoo.com - March 17 at 3:02 PMScilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitmentfinance.yahoo.com - March 8 at 10:33 AM Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNEQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. SRNEQ Media Mentions By Week SRNEQ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRNEQ News Sentiment▼0.000.42▲Average Medical News Sentiment SRNEQ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRNEQ Articles This Week▼00▲SRNEQ Articles Average Week Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNEQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SRNE News Today GENE News Today TTNP News Today CELZ News Today ONVO News Today BCDA News Today IKT News Today FRTX News Today PALI News Today FNCH News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SRNEQ) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
